Beyond CAR-T: New Engineered Immune Cell Types Head to the Clinic

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Biopharma Gets Serious, In a Hurry, About Virtual Clinical Trials
Cancer Drugmakers Seek to Broaden Use of Tissue-Agnostic Therapies
Solid Tumors Have Eluded CAR-T, But Novel Targets and Techniques Are At Hand
Automation and Miniaturization Are Upon Us: Gritstone’s Mission to Make Personalized Medicines